Univariate analyses of prognostic parameters
. | Analysis after induction therapy . | . | . | . | Analysis after consolidation therapy . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | RFS . | . | OS . | . | RFS . | . | OS . | . | ||||||
. | P . | RR (95% CI) . | P . | RR (95% CI) . | P . | RR (95% CI) . | P . | RR (95% CI) . | ||||||
| LD | .0001 | 0.312 (0.172-0.565) | n.s. | — | .00008 | 0.418 (0.270-0.645) | .005 | 0.408 (0.218-0.763) | ||||||
| Unfavorable karyotype | .0001 | 4.972 (2.213-11.173) | .079 | 3.265 (0.871-12.239) | .071 | 2.259 (0.932-5.472) | n.s. | — | ||||||
| WBC count | .059 | 1.03 (1.00-1.08)* | .020 | 1.11 (1.00-1.20)* | n.s. | — | n.s. | — | ||||||
| Percentage of BM blasts at diagnosis | n.s. | — | n.s. | — | .036 | 0.982 (0.966-0.999) | n.s. | — | ||||||
. | Analysis after induction therapy . | . | . | . | Analysis after consolidation therapy . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | RFS . | . | OS . | . | RFS . | . | OS . | . | ||||||
. | P . | RR (95% CI) . | P . | RR (95% CI) . | P . | RR (95% CI) . | P . | RR (95% CI) . | ||||||
| LD | .0001 | 0.312 (0.172-0.565) | n.s. | — | .00008 | 0.418 (0.270-0.645) | .005 | 0.408 (0.218-0.763) | ||||||
| Unfavorable karyotype | .0001 | 4.972 (2.213-11.173) | .079 | 3.265 (0.871-12.239) | .071 | 2.259 (0.932-5.472) | n.s. | — | ||||||
| WBC count | .059 | 1.03 (1.00-1.08)* | .020 | 1.11 (1.00-1.20)* | n.s. | — | n.s. | — | ||||||
| Percentage of BM blasts at diagnosis | n.s. | — | n.s. | — | .036 | 0.982 (0.966-0.999) | n.s. | — | ||||||
Only significant parameters are shown.
RFS indicates relapse-free survival; OS, overall survival; RR, risk ratio; CI, confidence interval; LD, log difference; BM, bone marrow; n.s., not significant; and —, not applicable.
Per 100 g/L.